# Biotech Growth Trust: The biotech rebound powered by innovation, valuations and pharma’s patent cliff

- Link: https://www.directorstalkinterviews.com/biotech-growth-trust-the-biotech-rebound-powered-by-innovation-valuations-and-pharma-s-patent-cliff/4121255901
- Published: 2026-07-08T14:22:30+01:00
- Author: Ethan Davis

**Biotech Growth Trust** (LON:BIOG) offers UK investors access to a global biotech
sector that Geoffrey Hsu believes is entering a powerful window of opportunity. 
With valuations at compelling levels, the FDA approving new drugs at a proactive
pace, and large pharmaceutical companies searching for acquisitions to replace revenue
lost to patent expiries, the case for biotech exposure is being driven by both scientific
progress and corporate urgency.

**Key Moments**

00:06 — Geoffrey Hsu introduces Biotech Growth Trust and its global biotech mandate

00:35 — Why now could be a compelling entry point for biotech investors01:02 — How
biotech innovation is creating new medicines for patients01:22 — The key characteristics
OrbiMed looks for in biotech companies01:59 — Why the portfolio is currently tilted
towards small and mid-cap biotech02:31 — Global exposure across the US, Europe and
China02:40 — Diversification across RNA, cell therapy, gene therapy and antibody-
drug conjugates03:27 — The M&A resurgence and why shareholders can benefit directly03:
55 — Big pharma’s patent cliff as a major driver of biotech acquisitions04:21 — 
What sets Biotech Growth Trust apart from other sector trusts04:42 — How OrbiMed’s
private equity platform supports public market diligence05:05 — Why China is becoming
an increasingly important source of biotech innovation

**Biotech Growth Trust** seeks to deliver capital appreciation by investing in leading
biotech opportunities worldwide. Managed by OrbiMed, a global healthcare specialist
with deep public and private market expertise, the Trust provides diversified exposure
across geographies, company stages, therapeutic areas and cutting-edge technologies
including RNA, cell therapy, gene therapy and antibody-drug conjugates.

Share on:
